Biodegradable stents for the treatment of refractory benign esophageal strictures: Systematic review and meta-analysis.

IF 3 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Digestion Pub Date : 2025-05-27 DOI:10.1159/000546377

Daniel Tyč, Nina Vaněčková, Josef Hanuš, Iva Selke Krulichová

{"title":"Biodegradable stents for the treatment of refractory benign esophageal strictures: Systematic review and meta-analysis.","authors":"Daniel Tyč, Nina Vaněčková, Josef Hanuš, Iva Selke Krulichová","doi":"10.1159/000546377","DOIUrl":null,"url":null,"abstract":"Introduction: Refractory benign esophageal strictures (RBES) pose significant clinical challenges. Biodegradable (BD) stents have emerged as alternatives to traditional stenting methods, offering the possibility of reducing the need for multiple procedures. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of BD stents in the treatment of RBES.Methods: The PubMed, Web of Science, Scopus, Cochrane, and Science Direct databases were searched according to the PRISMA statement. Studies that focused on the clinical outcomes of BD stents used in adult patients with RBES were included. Data on technical success and complication rates were analyzed using random-effects models. Efficacy data were analyzed using Kaplan-Meier analysis.Results: The review included 15 studies with 241 BD stent implantations. The technical success rates were consistently high in all studies. The median time to restenosis was 21 weeks, with survival rates of 38.4% at 26 weeks and 27.0% at 52 weeks. The rate of complications requiring intervention was relatively low, but significant hyperplasia and pain occurred in 16.4% and 8.8% of the cases, respectively. Significant heterogeneity was observed in hyperplasia-related outcomes, which required a detailed subgroup analysis to investigate the underlying causes.Conclusion: BD stents provide acceptable results in terms of efficacy and safety for the treatment of RBES. However, the evidence is limited owing to the lack of randomized controlled trials and comparative studies. Future research should focus on these areas to strengthen the clinical evidence regarding BD stents.","PeriodicalId":11315,"journal":{"name":"Digestion","volume":" ","pages":"1-23"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digestion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000546377","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Refractory benign esophageal strictures (RBES) pose significant clinical challenges. Biodegradable (BD) stents have emerged as alternatives to traditional stenting methods, offering the possibility of reducing the need for multiple procedures. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of BD stents in the treatment of RBES.

Methods: The PubMed, Web of Science, Scopus, Cochrane, and Science Direct databases were searched according to the PRISMA statement. Studies that focused on the clinical outcomes of BD stents used in adult patients with RBES were included. Data on technical success and complication rates were analyzed using random-effects models. Efficacy data were analyzed using Kaplan-Meier analysis.

Results: The review included 15 studies with 241 BD stent implantations. The technical success rates were consistently high in all studies. The median time to restenosis was 21 weeks, with survival rates of 38.4% at 26 weeks and 27.0% at 52 weeks. The rate of complications requiring intervention was relatively low, but significant hyperplasia and pain occurred in 16.4% and 8.8% of the cases, respectively. Significant heterogeneity was observed in hyperplasia-related outcomes, which required a detailed subgroup analysis to investigate the underlying causes.

Conclusion: BD stents provide acceptable results in terms of efficacy and safety for the treatment of RBES. However, the evidence is limited owing to the lack of randomized controlled trials and comparative studies. Future research should focus on these areas to strengthen the clinical evidence regarding BD stents.

查看原文本刊更多论文

可生物降解支架治疗难治性良性食管狭窄：系统回顾和荟萃分析。

难治性良性食管狭窄（RBES）是一项重大的临床挑战。生物可降解支架（BD）已经成为传统支架方法的替代品，提供了减少多次手术需求的可能性。本系统综述和荟萃分析旨在评估BD支架治疗RBES的有效性和安全性。方法：根据PRISMA声明检索PubMed、Web of Science、Scopus、Cochrane、Science Direct等数据库。纳入了针对成年RBES患者使用BD支架的临床结果的研究。采用随机效应模型分析技术成功率和并发症发生率的数据。疗效资料采用Kaplan-Meier分析。结果：本综述纳入15项研究，共241例BD支架植入。在所有研究中，技术成功率始终很高。再狭窄的中位时间为21周，26周和52周的生存率分别为38.4%和27.0%。需要干预的并发症发生率相对较低，但明显增生和疼痛发生率分别为16.4%和8.8%。在增生相关的结果中观察到显著的异质性，这需要详细的亚组分析来调查潜在的原因。结论：BD支架治疗RBES的疗效和安全性均可接受。然而，由于缺乏随机对照试验和比较研究，证据有限。今后的研究应集中在这些方面，以加强BD支架的临床证据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Digestion 医学-胃肠肝病学

CiteScore

7.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Digestion'' concentrates on clinical research reports: in addition to editorials and reviews, the journal features sections on Stomach/Esophagus, Bowel, Neuro-Gastroenterology, Liver/Bile, Pancreas, Metabolism/Nutrition and Gastrointestinal Oncology. Papers cover physiology in humans, metabolic studies and clinical work on the etiology, diagnosis, and therapy of human diseases. It is thus especially cut out for gastroenterologists employed in hospitals and outpatient units. Moreover, the journal''s coverage of studies on the metabolism and effects of therapeutic drugs carries considerable value for clinicians and investigators beyond the immediate field of gastroenterology.